Ignite Innovation Xentria Meitheal, the Collaboration Gateway

Prior to joining Xentria and Meitheal, Tom was Vice President of Global Alliance Management for Sagent Pharmaceuticals and was responsible for global ... 健友股份(603707)6月27日晚间公告，公司全资子公司香港健友（被许可方代表）及香港健友控股子公司Meitheal（被许可方）拟与Xentria签署许可协议，Xentria授予被许可方 ... Xentria Entered into an Exclusive Multi-Year License Agreement with Meitheal to Commercialize XTMAB-16 for Pulmonary Sarcoidosis in North America. Shots:. Xentria landed a nearly $700 million licensing agreement with Meitheal Pharmaceuticals, a local drugmaker that spun out Xentria in 2020. Xentria and Meitheal ink licensing deal for rare lung disease treatment in North America. Xentria will license its experimental pulmonary sarcoidosis drug to ... ... Meitheal, Organon, Pheon, Remegen, Samsung Bioepis, Sandoz, Sanyou, Shionogi, Sirnaomics, SK Bioscience, Xentria, Zymedi. Read More · Regulatory actions ... Xentria is a biologics development company working closely with Meitheal Pharmaceuticals (Chicago, IL), NKF Pharma (Nanking, China), and KinBio (Rehovot, Israel) ... NKF and Meitheal Announce Dr. Jiali Luo as General Manager of New Biopharmaceutical Business. Happenings. NKF and Meitheal Announce Dr. Jiali Luo as ... In addition, Victoria is the General Counsel & Corporate Secretary of Xentria, Inc. a biotech company focused on novel biologics and biosimilars, which was ... The European Medicines Agency (EMA) has granted XTMAB-16, Xentria's ... Earlier this year, Xentria entered into an agreement with Meitheal ...